Hôpital Notre-Dame is a hospital in Montreal, Quebec, Canada. It is located on Sherbrooke Street East in the borough of Ville-Marie, across from La Fontaine Park. It was established in 1880, and has been at its present site since 1924.

During the past decade, Centre hospitalier de l'universite de Montreal conducted 399 clinical trials. In the 10-year time frame, 399 clinical trials started and 91 clinical trials were completed, i.e. on average, 22.8% percent of trials that started reached the finish line to date. In the past 5 years, 150 clinical trials started and 56 clinical trials were completed. i.e. 37.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre hospitalier de l'universite de Montreal" #1 sponsor was "Centre hospitalier de l'Université de Montréal (CHUM)" with 210 trials, followed by "Radiation Therapy Oncology Group" with 38 trials sponsored, "Canadian Cancer Trials Group" with 21 trials sponsored, "NCIC Clinical Trials Group" with 18 trials sponsored and "National Cancer Institute (NCI)" with 18 trials sponsored. Other sponsors include 357 different institutions and companies that sponsored additional 181 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre hospitalier de l'universite de Montreal" #1 collaborator was "National Cancer Institute (NCI)" with 79 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 41 trials as a collaborator, "Centre de Recherche du Centre Hospitalier de l'Université de Montréal" with 34 trials as a collaborator, "Université de Montréal" with 17 trials as a collaborator and "NRG Oncology" with 15 trials as a collaborator. Other collaborators include 588 different institutions and companies that were collaborators in the rest 336 trials.

According to Clinical.Site data, the most researched conditions in "Centre hospitalier de l'universite de Montreal" are "Breast Cancer" (33 trials), "Prostate Cancer" (26 trials), "Lung Cancer" (21 trials), "Colorectal Cancer" (16 trials) and "Head and Neck Cancer" (15 trials). Many other conditions were trialed in "Centre hospitalier de l'universite de Montreal" in a lesser frequency.

Most popular intervention types in "Centre hospitalier de l'universite de Montreal" are "Drug" (345 trials), "Other" (126 trials), "Procedure" (94 trials), "Radiation" (90 trials) and "Device" (74 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (68 trials), "radiation therapy" (32 trials), "Paclitaxel" (15 trials), "Quality-of-Life Assessment" (14 trials) and "Laboratory Biomarker Analysis" (12 trials). Other intervention names were less common.

The vast majority of trials in "Centre hospitalier de l'universite de Montreal" are 552 trials for "All" genders, 71 trials for "Female" genders and 42 trials for "Male" genders.

Currently, there are 283 active trials in "Centre hospitalier de l'universite de Montreal". 7 are not yet recruiting, 162 are recruiting, 110 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 304 completed trials in Centre hospitalier de l'universite de Montreal, 3 suspended trials, and 46 terminated clinical trials to date.

Out of the total trials that were conducted in Centre hospitalier de l'universite de Montreal, 51 "Phase 1" clinical trials were conducted, 152 "Phase 2" clinical trials and 209 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 23 trials, and there were also 176 trials that are defined as “Not Applicable".